Rare disease trials differ from those in most other therapeutic areas because the indications are more complex and involve smaller patient populations. It is essential to understand the current disease landscape, the prior research, and the competitive clinical trial environment when posi¬tioning a new clinical trial within the rare disease space. This white paper discusses strategies for accelerating rare disease clinical development by lever¬aging data in a more evidence-based approach to guide the design of a trial; to understand treat¬ment trends; and to identify the best investigators, sites, and patients.
Explore related content and topics
Page
Healthcare Intelligence
Some people focus on their IQ—their intellectual and expertise-driven strategy. Others focus on their EQ—their ability to empathetically relate to…
Page
Data Services
Every day we’re making breakthroughs in how we use data to answer questions, but we’re also making breakthroughs in how our data is empowering our…
Webinar
Evidence Based and Site Focused Strategies to Enhance Clinical Trial Enrollment
Join PRA Health Sciences Vice President, Investigator Relations, Dr. Martin Lee, as he explores evidence based and site focused recruitment…